Skip to main content

Table 1 General characteristics of the included studies with case–control and cross-sectional design

From: Bladder cancer and human papillomavirus association: a systematic review and meta-analysis

First author

Study design

pub year

country

Continent

Method

Type of sample

Case

Positive (case)

Control

Positive (control)

Sorlozanoa et al. [14]

Case–control

2011

Spain

Europe

Nested PCR

Frozen

85

8

51

7

Polese et al. [15]

Case–control

2011

Italy

Europe

PCR

Frozen

114

81

140

108

Cai et al. [16]

Case–control

2011

Italy

Europe

PCR

Not indicated

78

51

59

21

Barghi et al. [17]

Cross-sectional

2012

Iran

Asia

PCR

FFPE

82

24

  

Panagiotakis et al. [18]

Case–control

2012

Greece

Europe

PCR

Frozen

30

0

30

0

Chapman-Fredricks et al. [19]

Cross-sectional

2013

USA

America

ISH

FFPE

14

0

  

Chapman-Fredricks et al. [19]

Cross-sectional

2013

USA

America

Hologic

FFPE

14

3

  

Shigehara et al. [20]

Cross-sectional

2013

Japan

Asia

PCR

FFPE

84

5

  

Berrada et al. [21]

Case–control

2013

Morocco

Africa

Nested PCR

Frozen

43

22

5

0

Alexander et al. [22]

Cross-sectional

2014

China

Asia

ISH

FFPE

36

0

  

Borkowska et al. [23]

Cross-sectional

2014

Poland

Europe

Array

Not indicated

104

14

  

Golovina et al. [24]

Cross-sectional

2014

Russia

Europe

PCR

Frozen

35

16

  

Kim et al. [25]

Case–control

2014

Korea

Asia

Array

FFPE

35

6

12

1

Pichler et al. [26]

Cross-sectional

2015

Austria

Oceania

PCR

FFPE

186

4

  

Schmid et al. [27]

Case–control

2015

Germany

Europe

PCR

Frozen

109

0

26

0

Anwar et al. [28]

Case–control

2015

Pakistan

Asia

PCR

FFPE

114

16

107

2

Golovina et al. [29]

Cross-sectional

2016

Russia

Europe

PCR

Frozen

101

38

  

Jorgensena et al. [30]

Cross-sectional

2018

Denmark

Europe

INNO-LiPA

FFPE

100

12

  

Llewellyn et al. [31]

Cross-sectional

2018

UK

Europe

PCR

Frozen

689

1

  

Uttam et al. [32]

Cross-sectional

2018

India

Asia

PCR

FFPE/Frozen

50

0

10

0

Abdollahzadeh et al. [33]

Case–control

2018

Iran

Asia

IHC

FFPE

67

15

30

1

Javanmard et al. [34]

Cross-sectional

2019

Iran

Asia

PCR

FFPE

110

89

  

Sarier et al. [35]

Case–control

2019

Turkey

Europe

PCR

Frozen

69

20

69

6

Collins et al. [36]

Cross-sectional

2020

USA

America

ISH

FFPE

33

0

  

Gordetsky et al. [37]

Cross-sectional

2020

USA

America

ISH

FFPE

207

1

  

Moghadam et al. [38]

Cross-sectional

2020

Iran

Asia

PCR

FFPE

106

24

  

Yan et al. [39]

Cross-sectional

2020

China

Asia

NGS

Frozen

146

42

  

Yildizhan et al. [40]

Case–control

2020

Turkey

Europe

PCR

FFPE

113

4

99

9